Alpha 2.0
Login Register
» Authors » Jeremy Lambert

Jeremy Lambert

Explore the profile of Jeremy Lambert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 320
Followers 0
Related Specialties
Health Services
General Medicine
Biochemistry
Top 10 Co-Authors
Benoit Arnould
Barbara Ink
Isabelle Guillemin
Vanessa Taieb
Alexia Marrel
Khadra Benmedjahed
Murtuza Bharmal
Dafna D Gladman
Laura C Coates
Nicolas Goffart
Published In
Patient
Patient Prefer Adherence
RMD Open
J Rehabil Med
Ophthalmic Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
Gladman D, Mease P, Gossec L, Husni M, Gottlieb A, Ink B, et al.
J Rheumatol . 2025 Feb; PMID: 39892885
Objective: To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were...
2.
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Warren R, Lebwohl M, Thaci D, Gooderham M, Pinter A, Paul C, et al.
Br J Dermatol . 2025 Jan; PMID: 39862230
Background: Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody...
3.
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Kristensen L, Tillett W, Nash P, Coates L, Mease P, Ogdie A, et al.
Ther Adv Musculoskelet Dis . 2024 Nov; 16:1759720X241288071. PMID: 39534481
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts health-related quality of life (HRQoL). In the phase III BE...
4.
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
Husni M, Mease P, Merola J, Tillett W, Goldammer N, Ink B, et al.
RMD Open . 2024 Sep; 10(3). PMID: 39313302
Objectives: To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3...
5.
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Augustin M, Gottlieb A, Lebwohl M, Pinter A, Warren R, Puig L, et al.
Dermatol Ther (Heidelb) . 2024 Sep; 14(10):2841-2857. PMID: 39285121
Introduction: With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity...
6.
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Viola F, Chi G, Holekamp N, Giocanti-Auregan A, Garcia-Layana A, Peto T, et al.
Ophthalmic Res . 2024 Aug; 67(1):516-527. PMID: 39208778
Introduction: Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) require frequent anti-vascular endothelial growth factor (VEGF) treatment and monitoring visits. We aimed to understand the burden of treatment...
7.
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Gossec L, Orbai A, de Wit M, Coates L, Ogdie A, Ink B, et al.
Rheumatology (Oxford) . 2024 May; 63(9):2399-2410. PMID: 38754125
Objectives: To evaluate 1-year bimekizumab efficacy in PsA from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire. Methods: BE OPTIMAL (NCT03895203; biologic DMARD [bDMARD]-naïve), BE COMPLETE...
8.
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Holekamp N, Gentile B, Giocanti-Auregan A, Garcia-Layana A, Peto T, Viola F, et al.
Ophthalmic Res . 2024 Apr; 67(1):311-321. PMID: 38679018
Introduction: Understanding patient perspectives of treatment may improve adherence and outcomes. This study explored real-world patient experiences with anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) and...
9.
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
Gossec L, Orbai A, Coates L, Gladman D, Ogdie A, Pelligra C, et al.
RMD Open . 2024 Jan; 10(1). PMID: 38296802
Objectives: To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change...
10.
Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis
Kivitz A, Ellis A, Shende V, Lambert J, Tatla D
Patient Prefer Adherence . 2023 Oct; 17:2451-2461. PMID: 37808274
Purpose: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, key drivers of chronic inflammation. Bimekizumab must be injected subcutaneously and so patients require...